Smiths Group plc announces the appointment of Bruno Angelici as a non-executive Director of the Company, and as a member of each of the Audit, Nomination and Remuneration Committees of the Board, with effect from 1 July, 2010. Mr. Angelici brings to the Board wide ranging international experience in the pharmaceutical and healthcare sectors.
Mr. Angelici pursued a highly successful 20-year career with AstraZeneca plc before retiring in 2009 as Executive Vice President, International, after previously holding responsibility for the company’s national operations in France and then in Japan. Prior to this he held a number of senior management roles during a decade at Baxter, a US based global supplier of medical devices.
A French citizen, Mr. Angelici sits on the Supervisory Board of Wolters Kluwer, a Dutch-based information services and publishing company, and is Chairman of the Supervisory Board of Reims Management School. He holds an MBA from the Kellogg School of Management in Chicago and has Business and Law degrees from Reims. He was received into the Legion d’honneur in December 2009.
Smiths Chairman Donald Brydon said: “I am delighted to welcome such a distinguished international executive on to the Board of Smiths Group. The Company will benefit greatly from Bruno’s wide business experience and global perspective, particularly in the healthcare-related market.”
Other than his present membership of the Supervisory Board of Wolters Kluwer NV, a publicly quoted company listed on Euronext Amsterdam, and his former non-executive directorship of Allied Domecq plc between 2003 and 2005, which was then a publicly quoted company, there is no other information concerning Mr Angelici which requires notification under LR 9.6.13 R of the Listing Rules of the UK Listing Authority.